MB
Monroe Biomedical Research at ObesityWeek 2026
Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website
Monroe Biomedical Research brings 3 presentations to ObesityWeek 2026 in National Harbor. Its sessions report clinical study results for obesity drug candidates. They cover CRB-913 in the CANYON-1 study, subcutaneous VK2735 and cardiometabolic measures in the VENTURE study, and the effects of enicepatide on body composition in adults with overweight or obesity.
| Organization | ObesityWeek 2026 Attendance |
|---|---|
MB Monroe Biomedical Research Monroe, NC | |
Clinical trial site network that owns its research sites, including the Louisville Metabolic and Atherosclerosis Research Center in Kentucky. | Poster Sun Nov 15 2:30pm–3:30pm Impact of SC VK2735 on Obesity Severity and Cardiometabolic Parameters in the VENTURE Study Interventional and clinical studiesObesity pharmacotherapy and drug development Poster Sun Nov 15 2:30pm–3:30pm Efficacy, Safety, and Tolerability of CRB-913 in the Phase 1b CANYON-1 Study Interventional and clinical studiesObesity pharmacotherapy and drug development Talk Mon Nov 16 5:45pm–6:00pm |
Find decision makers at Monroe Biomedical Research
Tell us what you sell and we’ll find the people at Monroe Biomedical Research most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction